Freestone Capital Holdings’s Faeth Therapeutics FTH Stock Holding History

Freestone Capital Holdings’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$288K	Buy	+9,679	New	+$301K	0.01%	443

Other funds holding FTH

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

RIS

Richmond Investment Services Mequon, Wisconsin $316M AUM 19.72% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Financial Consulate Hunt Valley, Maryland $899M AUM 14.82% 1-Year Est. Return

Freestone Capital Holdings's FTH Position: Q3 2026 in Review

Freestone Capital Holdings opened a new position in Faeth Therapeutics (FTH) in Q3 2026: 9,679 shares worth $288K. The stake represents 0.01% of the portfolio and ranks #443 among its holdings.

14 funds tracked by Wall St. Rank hold FTH as of Q3 2026.

Freestone Capital Holdings held 9,679 shares of Faeth Therapeutics worth $288K as of Q3 2026.
Faeth Therapeutics was a new Freestone Capital Holdings position in Q3 2026.
Faeth Therapeutics made up 0.01% of Freestone Capital Holdings's portfolio in Q3 2026, its #443 holding.
14 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2026.

Based on Freestone Capital Holdings's 13F filing for Q3 2026, filed 9 Nov 2026.